Ovarian Function Clinical Trials
A listing of Ovarian Function medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 211 clinical trials
A Phase Ib Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab, To Patients With Advanced Platinum-sensitive Ovarian Cancer
The study will include a safety run-in phase (Stage 1) and a randomization phase (Stage 2). The purpose of Stage 1 is to evaluate the safety of cobimetinib when administered in combination with niraparib (Cohort 1) and cobimetinib with niraparib plus atezolizumab (Cohort 2). Stage 1 will enable patient enrollment …
- 64 views
- 19 Oct, 2022
- 5 locations
Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer
This research study is evaluating the effectiveness of Zafirlukast to prevent tumor activity in participants with tumor marker-only relapsed ovarian cancer. The name of the study drug involved in this study is: Zafirlukast
- 0 views
- 12 Dec, 2021
- 1 location
Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
This is a prospective, interventional, single-arm, open-label, phase II study to evaluate the safety and efficacy of niraparib monotherapy as neoadjuvant therapy in patients with advanced ovarian cancer, primary peritoneal cancer, fallopian tube cancer ((FIGO stage III or IV), who can not achieve R0 tumor reduction surgery after imaging evaluation …
- 0 views
- 04 Nov, 2021
- 1 location
Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer
This trial will be a phase I dose-escalation study of lapatinib and paclitaxel for platinum-resistant ovarian cancer, which will establish the phase II dose for subsequent efficacy trials.
- 0 views
- 15 Dec, 2021
- 1 location
PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy
This is an open-label Phase Ib dose-escalation study to determine the safety, tolerability, and pharmacokinetics of PTC-596 when combined with and following conventional chemotherapy and as maintenance therapy as a capsule (weight based dosing) and a tablet (fixed dosing) in women with epithelial ovarian, fallopian tube or primary peritoneal cancer …
- 30 views
- 29 Jan, 2022
- 1 location
NeoVax With Nivolumab in Patients With Ovarian Cancer
This research study is evaluating a new type of vaccine called "Personalized NeoAntigen Cancer Vaccine" in combination with Nivolumab (Opdivo®) for ovarian cancer.
- 23 views
- 04 Oct, 2022
Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
Randomized phase 3 trial evaluating niraparib plus dostarlimab vs chemotherapy at physician's choice in the treatment of recurrent ovarian, fallopian tube or primary peritoneal cancer patients for which platinum is not an option
- 2 views
- 04 Sep, 2021
- 8 locations
Evaluation of Surgical Excision of Cardiophrenic Lymph Nodes in Patients With Advanced Ovarian Cancer
Evaluation of surgical excision of cardiophrenic lymph nodes in patients with advanced ovarian cancer
- 5 views
- 21 Jan, 2021
- 1 location
Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer
This study was designed to assess the safety and efficacy of neoadjuvant therapy with mitomycin C plus cisplatin (MP) in BRCA1-mutated ovarian cancer versus standard regimen (paclitaxel plus carboplatin (TP)).
- 0 views
- 18 Feb, 2021
- 1 location
Safety and Efficacy of AsiDNATM a DNA Repair Inhibitor Administered Intravenously in Addition to PARP Inhibitors in Patients With Relapsed Platinum Sensitive Ovarian Cancer Already Treated With PARP Inhibitors Since at Least 6 Months
The objective of REVOCAN study is to assess the abrogation of PARP inhibitors resistance in patients with relapsed platinum sensitive ovarian cancer treated with PARP inhibitors in maintenance since at least 6 months and who have only an increase of CA 125 without any progression according to RECIST criteria. AsiDNATM …
- 0 views
- 10 Oct, 2021
- 1 location